OS Therapies (OSTX) said Tuesday it closed the $6 million private placement financing of 1.5 million units.
Each unit in the offering includes one share of series A senior convertible preferred stock and one warrant to purchase one common share, according to the company.
The units were priced at $4 apiece with a $4 conversion price of preferred stock into one common share and a $4.40 per share exercise price of the warrants, OS Therapies added.
The company said proceeds from the private placement will be used for working capital and general capital purposes.
OS Therapies expects the capital raised to sustain operations into 2026 and anticipates delivering clinical data and biologics license application requirements needed to obtain US Food and Drug Administration authorization for the commercialization of OST-HER2 to prevent recurrent, resected metastatic osteosarcoma in the US.
Shares of OS Therapies were down more than 10% in recent trading.
Price: 4.22, Change: -0.48, Percent Change: -10.15
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。